CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference
CervoMed Inc. (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, will participate in the Canaccord Genuity 45th Annual Growth Conference in Boston, MA. The company's management will engage in a fireside chat on Tuesday, August 12, 2025, at 2:00 PM ET.
The presentation will be available via webcast, accessible through the company's investor relations website. During the conference, which runs from August 12-14, 2025, management will also conduct one-on-one meetings with investors.
CervoMed Inc. (NASDAQ: CRVO), un'azienda in fase clinica che sviluppa trattamenti per disturbi neurologici legati all'età, parteciperà alla 45ª Conferenza Annuale sulla Crescita di Canaccord Genuity a Boston, MA. Il management dell'azienda prenderà parte a una discussione informale il martedì 12 agosto 2025, alle 14:00 ET.
La presentazione sarà disponibile in diretta streaming, accessibile tramite il sito web dedicato agli investitori dell'azienda. Durante la conferenza, che si svolgerà dal 12 al 14 agosto 2025, il management terrà anche incontri individuali con gli investitori.
CervoMed Inc. (NASDAQ: CRVO), una empresa en etapa clínica que desarrolla tratamientos para trastornos neurológicos relacionados con la edad, participará en la 45ª Conferencia Anual de Crecimiento de Canaccord Genuity en Boston, MA. La dirección de la empresa participará en una charla informal el martes 12 de agosto de 2025 a las 2:00 PM ET.
La presentación estará disponible vía webcast, accesible a través del sitio web de relaciones con inversores de la empresa. Durante la conferencia, que se llevará a cabo del 12 al 14 de agosto de 2025, la dirección también realizará reuniones individuales con inversores.
CervoMed Inc. (NASDAQ: CRVO)는 노화 관련 신경 질환 치료제를 개발하는 임상 단계 기업으로, 매사추세츠주 보스턴에서 열리는 Canaccord Genuity 제45회 연례 성장 컨퍼런스에 참가합니다. 회사 경영진은 2025년 8월 12일 화요일 오후 2시(동부시간)에 진행되는 비공식 대화에 참여할 예정입니다.
발표는 회사의 투자자 관계 웹사이트를 통해 웹캐스트로 제공됩니다. 2025년 8월 12일부터 14일까지 진행되는 컨퍼런스 기간 동안 경영진은 투자자들과 1:1 미팅도 진행할 예정입니다.
CervoMed Inc. (NASDAQ : CRVO), une société en phase clinique développant des traitements pour les troubles neurologiques liés à l'âge, participera à la 45e conférence annuelle sur la croissance de Canaccord Genuity à Boston, MA. La direction de l'entreprise prendra part à une discussion informelle le mardi 12 août 2025 à 14h00 ET.
La présentation sera disponible en webcast, accessible via le site web des relations investisseurs de l'entreprise. Pendant la conférence, qui se déroulera du 12 au 14 août 2025, la direction tiendra également des réunions individuelles avec les investisseurs.
CervoMed Inc. (NASDAQ: CRVO), ein klinisch tätiges Unternehmen, das Behandlungen für altersbedingte neurologische Erkrankungen entwickelt, wird an der 45. jährlichen Wachstumskonferenz von Canaccord Genuity in Boston, MA, teilnehmen. Das Management des Unternehmens wird an einem Gespräch am Kamin am Dienstag, den 12. August 2025, um 14:00 Uhr ET teilnehmen.
Die Präsentation wird per Webcast verfügbar sein und kann über die Investor-Relations-Website des Unternehmens abgerufen werden. Während der Konferenz, die vom 12. bis 14. August 2025 stattfindet, wird das Management auch Einzelgespräche mit Investoren führen.
- None.
- None.
BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the CG 45th Annual Growth Conference being held in Boston, MA, on Tuesday, August 12 to Thursday, August 14, 2025.
Presentation Details
Format: Fireside Chat
Date: Tuesday, August 12, 2025
Time: 2:00 PM ET
Webcast Link: https://wsw.com/webcast/canaccord108/crvo/2537558
The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.
About CervoMed
CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b trial in patients with DLB.
Investor Contact:
PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
617-430-7579
FAQ
When is CervoMed (NASDAQ:CRVO) presenting at the Canaccord Genuity Conference?
How can investors access CervoMed's (CRVO) Canaccord conference presentation?
What is CervoMed's (CRVO) main business focus?
What type of meetings will CervoMed (CRVO) conduct at the Canaccord conference?
